Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies
- Conditions
- LymphomaLung Cancer
- Interventions
- Genetic: DNA analysisGenetic: RNA analysisGenetic: gene expression analysisGenetic: polymorphism analysisOther: biologic sample preservation procedureOther: flow cytometryOther: medical chart review
- Registration Number
- NCT01567722
- Lead Sponsor
- AIDS Malignancy Consortium
- Brief Summary
RATIONALE: Collecting and studying tissue samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research trial studies collecting tissue samples from patients with HIV-related malignancies.
- Detailed Description
OBJECTIVES:
* To obtain high-quality, clinically annotated tissue from patients with human immunodeficiency virus (HIV)-1 malignancy.
* To study clinical, genetic, and immunologic parameters that have prognostic significance and/or are involved in the initiation and progression of HIV-1 malignancies, including complete genomic sequence determination of HIV-associated diffuse large B-cell lymphomas, lung cancer, anal cancer, and cervical cancer.
OUTLINE: This is a multicenter study.
Patients undergo tumor, lymph node, bone marrow, or skin biopsy, and peripheral blood mononuclear cells collection. Samples are submitted to the AIDS Malignancy Consortium (AMC) Biorepository and transferred to the AIDS and Cancer Specimen Resource (ACSR). Samples are then analyzed by the Genome Science Center of British Columbia (GSC-BC) and the HIV+ Tumor Molecular Characterization Project (HTMCP) for full genomic sequencing analysis that may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies by flow cytometry, cytogenetics, and molecular studies. Patients' clinical data, demographics, and treatment given are also collected prospectively in order to record treatment outcome and toxicity.
Patients are followed up at 6 months, 1 year, and 2 years for data-reporting purposes.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 114
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description HIV-positive diffuse large B-cell lymphoma cases gene expression analysis Tissue collection for genomic sequencing from persons with a diagnosis of HIV and diffuse large B-cell lymphoma. HIV-positive diffuse large B-cell lymphoma cases biologic sample preservation procedure Tissue collection for genomic sequencing from persons with a diagnosis of HIV and diffuse large B-cell lymphoma. HIV-positive diffuse large B-cell lymphoma cases DNA analysis Tissue collection for genomic sequencing from persons with a diagnosis of HIV and diffuse large B-cell lymphoma. HIV-positive diffuse large B-cell lymphoma cases RNA analysis Tissue collection for genomic sequencing from persons with a diagnosis of HIV and diffuse large B-cell lymphoma. HIV-positive diffuse large B-cell lymphoma cases polymorphism analysis Tissue collection for genomic sequencing from persons with a diagnosis of HIV and diffuse large B-cell lymphoma. HIV-positive lung cancer cases RNA analysis Tissue collection for genomic sequencing from persons with a diagnosis of HIV and lung cancer. HIV-positive diffuse large B-cell lymphoma cases flow cytometry Tissue collection for genomic sequencing from persons with a diagnosis of HIV and diffuse large B-cell lymphoma. HIV-positive lung cancer cases DNA analysis Tissue collection for genomic sequencing from persons with a diagnosis of HIV and lung cancer. HIV-positive lung cancer cases medical chart review Tissue collection for genomic sequencing from persons with a diagnosis of HIV and lung cancer. HIV-positive diffuse large B-cell lymphoma cases medical chart review Tissue collection for genomic sequencing from persons with a diagnosis of HIV and diffuse large B-cell lymphoma. HIV-positive lung cancer cases flow cytometry Tissue collection for genomic sequencing from persons with a diagnosis of HIV and lung cancer. HIV-positive lung cancer cases gene expression analysis Tissue collection for genomic sequencing from persons with a diagnosis of HIV and lung cancer. HIV-positive lung cancer cases biologic sample preservation procedure Tissue collection for genomic sequencing from persons with a diagnosis of HIV and lung cancer. HIV-positive lung cancer cases polymorphism analysis Tissue collection for genomic sequencing from persons with a diagnosis of HIV and lung cancer.
- Primary Outcome Measures
Name Time Method Collection of Tissue Specimen From Study Participants Study entry (prior to chemotherapy initiation) Summary of the specimens available by study arm
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (14)
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
University of Pennsylvania - Abramson Cancer Center at Pennsylvania Hospital
🇺🇸Philadelphia, Pennsylvania, United States
John H. Stroger Hospital of Cook County
🇺🇸Chicago, Illinois, United States
Harborview Madison Clinic
🇺🇸Seattle, Washington, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Louisiana State University Public Hospital
🇺🇸New Orleans, Louisiana, United States
UCLA Clinical AIDS Research and Education (CARE) Center
🇺🇸Los Angeles, California, United States
Moores UCSD Cancer Center
🇺🇸La Jolla, California, United States
Albert Einstein Cancer Center at Albert Einstein College of Medicine
🇺🇸Bronx, New York, United States
UNC Lineberger Comprehensive Cancer Center
🇺🇸Chapel Hill, North Carolina, United States
University of Miami
🇺🇸Miami, Florida, United States
Virginia Mason Medical Center
🇺🇸Seattle, Washington, United States
George Washington University
🇺🇸Washington, District of Columbia, United States
Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States